CyPath Lung Volume Jumps 216% in Q2, but Cash Drops to $2.4M for bioAffinity
BIAF is trading near its 52-week low of $0.513 (1.4% above the low).
Summary
bioAffinity Technologies reported Q2 2026 results with a 216% surge in CyPath Lung test volume and $1.5M in revenue, but cash fell to $2.4M, intensifying financing urgency amid a Nasdaq delisting threat.
Key Events · Earnings and Guidance · BIAF
-
CyPath Lung Volume Surges 216%
Test volume in Q2 2026 jumped 216% year-over-year, with 1,097 reports delivered in the first half of 2026 versus 390 in the same period of 2025. Revenue rose 19% to $1.5 million.
-
Cash Runway Shrinks to $2.4M
Cash and equivalents fell from $6.4 million at year-end 2025 to $2.4 million as of June 30, 2026, after a $3.4 million net loss in Q2. A $3.2 million public offering in June 2026 provided a short-term bridge, but the burn rate remains high.
-
Nasdaq Delisting Threat Looms
A Nasdaq delisting notice arrived on July 31, 2026, for failing the $1 minimum bid price rule. The stock trades at $0.52, near its 52-week low, and faces potential delisting if it cannot regain compliance.
-
Clinical Trial and Pipeline Progress
Patient enrollment began for a longitudinal clinical trial of CyPath Lung at 11 sites, including VA and military medical centers. Positive preliminary data emerged for topical skin cancer treatments, and the pipeline expanded into asthma and COPD diagnostics.
Analysis · BIAF · Industrial Applications And Services
bioAffinity Technologies posted a mixed Q2 2026. CyPath Lung test volume soared 216% year-over-year, and revenue climbed 19% to $1.5 million, signaling accelerating commercial traction. Yet the company burned through $4 million in cash during the quarter, leaving only $2.4 million as of June 30—a dangerously thin runway given its going-concern warning and a recent Nasdaq delisting notice. The strong operational momentum is overshadowed by the urgent need for additional financing, which likely means more dilution for shareholders. Trading near its 52-week low of $0.51, the stock reflects the market's focus on survival risk over growth potential.
At the time of this filing, BIAF was trading at $0.52 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.51 to $13.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.